FDA Panels Should Focus on Science, Not Emotion, Drug Chief Says (1)

June 14, 2021, 9:14 PM; Updated: June 15, 2021, 3:28 PM

The FDA’s external scientific advisers need to remove emotional “overtones” from their deliberations and focus on scientific decisions, the agency’s drug chief said Monday.

Patrizia Cavazzoni didn’t name a specific panel, but her comments came just days after three members of a Food and Drug Administration advisory committee stepped down after the agency’s controversial decision to approve Biogen Inc.’s Alzheimer’s drug Aduhelm.

“Advisory committees maybe need to give some thought as to how to get back to the fundamental reasons for advisory committees, which is really listening to thoughtful input from experts in response to thoughtful questions that we ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.